


# Healthcare Services

Quarterly Update | Q4 2020



# Industry Overview

## M&A Transactions & Performance



Source: Capital IQ. Data as of December 31, 2020

Above noted mid-market M&A activity includes disclosed transactions not exceeding a total transaction value of \$500 million. All figures are in CAD.

### Canadian Transactions

**64**

### Canadian Transaction Value

**\$639 million**

(+15.3% vs. Q3 2020)

### US Transaction Value


**\$7.7 billion**

(+6.3% vs. Q3 2020)

### US Transactions

**460**

Healthcare merger and acquisition (M&A) activity in the fourth quarter of 2020 exceeded \$8.3 billion in disclosed transaction value across 524 deals in Canada and the US. The average deal size among disclosed transactions was \$15.9 million, a slight decline from \$18.2 million in the third quarter of 2020. In Canada, the top Healthcare sub-sectors for deal activity in the quarter were pharmaceuticals (16), healthcare technology (13), healthcare services (11) and drug retail (9). Together, these sub-sectors accounted for over 77% of Canadian Healthcare deal volume. In 2020, industry EV/EBITDA multiples (based on private equity transactions listed below) increased 27% from the previous year and averaged a multiple of 7.1x for lower mid-market transaction values (10 – 25 million range).



Source: GF Data. Data as of November 2020.

# Select Recent M&A Transactions



+  
**Upjohn**  
A Pfizer Division

formed



Closed	Nov. 16, 2020
Structure	All-stock
TEV/EBITDA	9.7x (Dec-31)
Location (Vendor)	Pennsylvania, USA

- Viatris Inc. (NasdaqGS:VTRS) formed from the merger of Pfizer's global off-patent drug business, Upjohn Inc., with generic drug manufacturer Mylan. Transaction was initially announced in July 2019.
- Pfizer shareholders will own 57% of the combined company while Mylan's stockholders will get a 43% stake in the new entity.
- Viatris will maintain brands such as EpiPen and Lipitor.



**DRUG MART**

acquired

**FOREWEST HOLDINGS INC.**

Closed	Oct. 28, 2020
TEV	Not disclosed
TEV/EBITDA	Not disclosed
Location (Vendor)	Langley, BC

- Rx Drug Mart, a portfolio company of Persistence Capital Partners, has acquired Forewest Holdings Inc., an operator of 35 pharmacy locations in British Columbia and Alberta.
- The acquisition increased Rx Drug Mart's total pharmacy locations by 37%, further strengthening its presence in Western Canada.
- Of the 35 pharmacies acquired, Rx Drug Mart fully owns 14 and holds equal or majority interests in the remaining 21.
- Rx Drug Mart network of independent pharmacies across Canada total 131 locations with 1,600 employees.



**WELL Health  
TECHNOLOGIES CORP**

acquired



**ExcelleMD**  
MÉDECINE PRIVÉE



**doctorcare**



Closed	Jan. 4, 2021
Consideration	\$4.75 million
Location (Vendor)	Toronto, ON

Closed	Dec. 8, 2020
Consideration	\$6.75 million

Montreal, QC

Closed	Nov. 11, 2020
Consideration	\$31 million (60%)

Vancouver, BC

Closed	Nov. 1, 2020
Consideration	\$35.8 million

Toronto, ON

Closed	Nov. 1, 2020
Consideration	\$1.1 million (51%)

Coquitlam, BC

- WELL Health Technologies Corp. (TSX:WELL) is an omni-channel digital health company providing electronic medical records (EMR) software services, telehealth services and cybersecurity related solutions. It also owns and operates 20 medical clinics, providing digital EMR software and services to approximately 2,000 medical clinics across Canada. The Company engaged in five healthcare related acquisitions over the past quarter.
- October 2020: the Company had completed a bought deal public offering of common shares for gross proceeds totalling over \$80.5 million. The use of net financing proceeds was specified for inorganic growth, acquisition of additional clinical and digital assets, and for general working capital.

# Industry Overview

## Pharmacies and Drug Stores in Canada

The Pharmacy and Drug Store industry includes the retailing of prescription and over-the-counter medications, health and beauty items, toiletries, and consumable goods directly to consumers.

### Industry Glance

2020 Revenue

**\$46.7B**

Annual Growth 2015 – 2020

**3.9%**


Projected Annual Growth 2020 – 2025

**1.7%**

Number of Businesses in 2020

**6,620**

### Products and Services Segmentation (2020)



- Prescription pharmaceuticals
- Personal and beauty products
- Nonprescription pharmaceuticals
- Other home health products

## Dentistry in Canada

The Dental industry captures establishments of licenced dentists engaged in private or group practice offering orthodontics, periodontics, surgery, prevention, and other products and services.

### Industry Glance

2020 Revenue

**\$16.2B**

Annual Growth 2015 – 2020

**1.3%**


Projected Annual Growth 2020 – 2025

**2.9%**

Number of Businesses in 2020

**26,572**





### Products and Services Segmentation (2020)



- Restorative
- Prevention
- Surgery
- Orthodontics
- Prosthodontics
- Other

# Macroeconomic Indicators


The Healthcare industry is affected by a number of key macroeconomic industry growth drivers. Below, we highlight total public and private health expenditure, per capita disposable income, national unemployment rates, and the aging population in Canada. According to economic trend projections, Canada and the US will experience short-term volatility but figures are expected to improve starting in 2021, supporting the view of continuing industry stability and growth.




# Public Comparable Analysis

## Growth, Margins & Multiples


### LTM Revenue Growth




### NTM Revenue Growth




### LTM EBITDA Margin




### NTM EBITDA Margin



### LTM EV/EBITDA



### NTM EV/EBITDA



Source: Capital IQ. Data as of December 31, 2020.


Valuation details provided on page 8.

"LTM" refers to last twelve months. "NTM" refers to next twelve months.


# Public Comparable Analysis

## Performance Analysis


### Healthcare Peer Group Share Price Performance – Q4



### Share Price Performance – LTM



### Historical LTM EV/EBITDA – Q4



Source: Capital IQ. Data as of December 31, 2020.

Further details provided on page 8.

"LTM" refers to last twelve months.

# Public Comparable Analysis

## Trading Multiples & Operating Statistics



We have selected a group of publicly traded healthcare entities for this high-level analysis. These public companies help act as a proxy for the industry and provide strong industry context.

(Figures in CAD millions, except percentages and ratios)

Company	Market Capitalization	Enterprise Value	LTM Operating Figures			NTM Consensus Estimates			Valuation		
			Revenue	Revenue Growth	EBITDA	Margin	Revenue	EBITDA Margin	NTM EV/EBITDA	LTM EV/EBITDA	LTM EV/REV
<b>Retail Pharmacy</b>											
CVS Health Corporation	\$113,912	\$210,103	\$353,452	9.0%	\$29,027	8.2%	(0.5%)	6.2%	9.7x	7.6x	0.6x
Rite Aid Corporation	\$1,078	\$9,157	\$30,964	10.5%	\$1,841	5.9%	(0.1%)	2.1%	14.2x	5.0x	0.3x
CareRx Corporation	\$94	\$161	\$148	21.1%	\$7	4.7%	32.2%	10.2%	8.3x	23.2x	1.1x
<b>Median</b>	<b>\$1,078</b>	<b>\$9,157</b>	<b>\$30,964</b>	<b>10.5%</b>	<b>\$1,841</b>	<b>5.9%</b>	<b>(0.1%)</b>	<b>6.2%</b>	<b>9.7x</b>	<b>7.6x</b>	<b>0.6x</b>
<b>Mean</b>	<b>\$38,361</b>	<b>\$73,140</b>	<b>\$128,188</b>	<b>13.5%</b>	<b>\$10,291</b>	<b>6.3%</b>	<b>10.5%</b>	<b>6.1%</b>	<b>10.7x</b>	<b>11.9x</b>	<b>0.7x</b>
<b>Pharmaceuticals</b>											
Johnson & Johnson	\$527,913	\$536,803	\$105,229	0.6%	\$34,363	32.7%	8.8%	34.1%	14.2x	15.5x	5.2x
Merck & Co., Inc.	\$263,704	\$291,053	\$63,083	3.0%	\$25,323	40.1%	3.7%	41.4%	10.7x	12.0x	4.8x
Pfizer Inc.	\$260,707	\$328,073	\$65,240	(8.3%)	\$26,195	40.2%	0.0%	39.3%	12.7x	13.2x	5.3x
Viatris Inc.	\$28,654	\$43,646	\$15,341	1.1%	\$4,719	30.8%	46.5%	38.1%	5.1x	9.7x	3.0x
Bausch Health Companies Inc.	\$9,410	\$39,270	\$10,709	(5.4%)	\$4,156	38.8%	0.3%	40.2%	9.3x	9.9x	3.8x
<b>Median</b>	<b>\$260,707</b>	<b>\$291,053</b>	<b>\$63,083</b>	<b>0.6%</b>	<b>\$25,323</b>	<b>38.8%</b>	<b>3.7%</b>	<b>39.3%</b>	<b>10.7x</b>	<b>12.0x</b>	<b>4.8x</b>
<b>Mean</b>	<b>\$218,078</b>	<b>\$247,769</b>	<b>\$51,920</b>	<b>(1.8%)</b>	<b>\$18,951</b>	<b>36.5%</b>	<b>11.9%</b>	<b>38.6%</b>	<b>10.4x</b>	<b>12.0x</b>	<b>4.4x</b>
<b>Pharmaceutical Distributors</b>											
Walgreens Boots Alliance, Inc.	\$44,002	\$96,501	\$183,846	3.0%	\$10,066	5.5%	0.7%	4.8%	11.1x	8.3x	0.5x
McKesson Corporation	\$35,582	\$45,882	\$312,028	5.5%	\$6,361	2.0%	0.6%	1.9%	7.9x	7.5x	0.2x
AmerisourceBergen Corporation	\$25,443	\$25,671	\$253,005	5.7%	\$3,477	1.4%	1.2%	1.3%	7.6x	7.7x	0.1x
Cardinal Health, Inc.	\$20,025	\$25,118	\$206,043	4.7%	\$3,575	1.7%	1.1%	1.8%	6.8x	7.3x	0.1x
<b>Median</b>	<b>\$30,513</b>	<b>\$35,776</b>	<b>\$229,524</b>	<b>5.1%</b>	<b>\$4,968</b>	<b>1.9%</b>	<b>0.9%</b>	<b>1.8%</b>	<b>7.8x</b>	<b>7.6x</b>	<b>0.1x</b>
<b>Mean</b>	<b>\$31,263</b>	<b>\$48,293</b>	<b>\$238,731</b>	<b>4.7%</b>	<b>\$5,870</b>	<b>2.7%</b>	<b>0.9%</b>	<b>2.4%</b>	<b>8.4x</b>	<b>7.7x</b>	<b>0.2x</b>
<b>Healthcare Service Providers</b>											
HCA Healthcare, Inc.	\$70,908	\$106,895	\$67,634	1.3%	\$14,013	20.7%	1.8%	19.4%	8.0x	8.0x	1.7x
Universal Health Services, Inc.	\$14,888	\$18,604	\$15,146	1.2%	\$2,664	17.6%	(0.0%)	15.4%	8.0x	7.3x	1.3x
Tenet Healthcare Corporation	\$5,369	\$24,215	\$23,357	(4.2%)	\$3,358	14.4%	4.8%	15.4%	6.7x	7.5x	1.1x
Community Health Systems, Inc.	\$1,089	\$16,699	\$15,928	(10.6%)	\$1,851	11.6%	(2.2%)	13.4%	8.4x	9.4x	1.1x
<b>Median</b>	<b>\$10,128</b>	<b>\$21,409</b>	<b>\$19,643</b>	<b>(1.5%)</b>	<b>\$3,011</b>	<b>16.0%</b>	<b>0.9%</b>	<b>15.4%</b>	<b>8.0x</b>	<b>7.8x</b>	<b>1.2x</b>
<b>Mean</b>	<b>\$23,063</b>	<b>\$41,603</b>	<b>\$30,517</b>	<b>(3.1%)</b>	<b>\$5,471</b>	<b>16.1%</b>	<b>1.1%</b>	<b>15.9%</b>	<b>7.8x</b>	<b>8.1x</b>	<b>1.3x</b>
<b>Healthcare/Dental Equipment &amp; Supplies</b>											
Becton, Dickinson and Company	\$92,732	\$112,521	\$22,806	(1.0%)	\$6,402	28.1%	7.2%	29.6%	15.6x	18.4x	5.2x
Baxter International Inc.	\$52,227	\$55,836	\$15,363	3.4%	\$3,952	25.7%	(0.5%)	22.2%	16.4x	14.8x	3.8x
DENTSPLY SIRONA Inc.	\$14,581	\$15,934	\$4,492	(15.2%)	\$929	20.7%	8.1%	22.5%	14.8x	17.9x	3.7x
Henry Schein, Inc.	\$12,164	\$14,450	\$12,904	(1.7%)	\$1,157	9.0%	8.1%	8.6%	12.2x	13.1x	1.2x
Patterson Companies, Inc.	\$3,594	\$4,439	\$7,285	(0.7%)	\$446	6.1%	3.6%	5.5%	10.8x	10.3x	0.6x
<b>Median</b>	<b>\$14,581</b>	<b>\$15,934</b>	<b>\$12,904</b>	<b>(1.0%)</b>	<b>\$1,157</b>	<b>20.7%</b>	<b>7.2%</b>	<b>22.2%</b>	<b>14.8x</b>	<b>14.8x</b>	<b>3.7x</b>
<b>Mean</b>	<b>\$35,060</b>	<b>\$40,636</b>	<b>\$12,570</b>	<b>(3.1%)</b>	<b>\$2,577</b>	<b>17.9%</b>	<b>5.3%</b>	<b>17.7%</b>	<b>14.0x</b>	<b>14.9x</b>	<b>2.9x</b>

# About Us



MNP Corporate Finance (MNPCF) has a dedicated team of over 60 merger, acquisition, and transaction professionals across Canada. MNPCF works with clients in virtually all industries as they prepare, plan and execute transactions.

Our typical transactions range in value between \$3 million and \$300 million.

## Local and International Reach

MNP is a participating firm within Praxity, a unique global alliance of independent accounting/advisory firms created to answer global business needs. As a member of Praxity, we are able to offer access to corporate finance, accounting and tax advisory services worldwide. We are also affiliated with Corporate Finance Cross Border, which consists of 170+ M&A professionals in more than 30 countries.



### CFxBorder - Global Reach with Local Relationships

Our corporate finance team through CFxB consists of 170 plus M&A professionals in more than 30 countries

## Services

- Divestitures
- Acquisitions
- Debt Financing
- Due Diligence
- Transaction Advisory Services

## Recently Closed Deals (National)



# About Us



## Deal Experience

Since our inception, our team has advised on hundreds of transactions, in a wide range of industries with diverse enterprise values. In the past six years alone we have completed over 125 transactions worth over \$2 billion (not including due diligence engagements).

## Industry Experience

- Food & Beverage
- Retail & Distribution
- Manufacturing
- Agriculture
- Automotive
- Materials
- Healthcare
- Pharmaceutical
- Transportation
- Construction
- Software
- Financial Services
- Technology
- Energy
- Oilfield Services
- Real Estate


## Hands-on Approach

Current M&A transactions require a hands-on approach from start to finish including the active engagement of senior resources. Our senior resources are dedicated to our clients and are available as necessary and appropriate. We keep our clients regularly informed of the engagement status, issues we are encountering, successes, and overall progress.

## Integrated Service Offering

We draw on the vast experience and deep specialist knowledge network of our partners locally, nationally and internationally as specialty issues arise, such as pre-transaction tax planning, transaction structuring, estate planning, valuation, due diligence, performance improvement, and risk management.

## Recently Closed Deals (National)




# Leadership Team

## Transaction Leadership



**Brett Franklin**  
President  
[Brett.Franklin@mnp.ca](mailto:Brett.Franklin@mnp.ca)  
204.336.6190



**Aleem Bandali**  
Managing Director  
[Aleem.Bandali@mnp.ca](mailto:Aleem.Bandali@mnp.ca)  
778.374.2140



**Dale Antonsen**  
Managing Director  
[Dale.Antonsen@mnp.ca](mailto:Dale.Antonsen@mnp.ca)  
250.979.2578



**Mike Reynolds**  
Managing Director  
[Mike.Reynolds@mnp.ca](mailto:Mike.Reynolds@mnp.ca)  
587.702.5909



**Mark Regehr**  
Managing Director  
[Mark.Regehr@mnp.ca](mailto:Mark.Regehr@mnp.ca)  
780.969.1404



**Erik St-Hilaire**  
Managing Director  
[Erik.St-Hilaire@mnp.ca](mailto:Erik.St-Hilaire@mnp.ca)  
204.336.6200



**Stephen Shaw**  
Managing Director  
[Stephen.Shaw@mnp.ca](mailto:Stephen.Shaw@mnp.ca)  
416.515.3883



**Dan Porter**  
Managing Director  
[Dan.Porter@mnp.ca](mailto:Dan.Porter@mnp.ca)  
416.515.3877




**Kevin Tremblay**  
Managing Director  
[Kevin.Tremblay@mnp.ca](mailto:Kevin.Tremblay@mnp.ca)  
647.943.4051



**Jon Edgett**  
Managing Director  
[Jon.Edgett@mnp.ca](mailto:Jon.Edgett@mnp.ca)  
519.772.7460



**Patrick Khouzam**  
Managing Director  
[Patrick.Khouzam@mnp.ca](mailto:Patrick.Khouzam@mnp.ca)  
514.228.7874



**Craig Maloney**  
Managing Director  
[Craig.Maloney@mnp.ca](mailto:Craig.Maloney@mnp.ca)  
902.493.5430

## Due Diligence Leadership



**Johnny Earl**  
Managing Director  
[Johnny.Earl@mnp.ca](mailto:Johnny.Earl@mnp.ca)  
604.637.1514



**John Caggianiello**  
Managing Director  
[John.Caggianiello@mnp.ca](mailto:John.Caggianiello@mnp.ca)  
416.513.4177